Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M L Slovak

Showing results (81-90 of 94) with videos related to

Pageof 10
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 1, 2009
Acute leukemia and myelodysplasia after adjuvant chemotherapy for breast cancer: durable remissions after hematopoietic stem cell transplantationV Pullarkat, M L Slovak, A Dagis, et al.
Blood|July 27, 1999
Frequency and clinical significance of the expression of the multidrug resistance proteins MDR1/P-glycoprotein, MRP1, and LRP in acute myeloid leukemia: a Southwest Oncology Group StudyC P Leith, K J Kopecky, I M Chen, et al.
Blood|June 5, 2001
The Burkitt-like lymphomas: a Southwest Oncology Group study delineating phenotypic, genotypic, and clinical featuresR M Braziel, D A Arber, M L Slovak, et al.
Blood|November 24, 2001
Benefit of cyclosporine modulation of drug resistance in patients with poor-risk acute myeloid leukemia: a Southwest Oncology Group studyA F List, K J Kopecky, C L Willman, et al.
Bone Marrow Transplantation|August 29, 2007
Reduced-intensity conditioning for allogeneic hematopoietic stem cell transplantation with fludarabine and melphalan is associated with durable disease control in myelodysplastic syndromeR Nakamura, R Rodriguez, J Palmer, et al.
Cancer Research|April 1, 1993
Overexpression of a M(r) 110,000 vesicular protein in non-P-glycoprotein-mediated multidrug resistanceR J Scheper, H J Broxterman, G L Scheffer, et al.
Blood|December 9, 2000
Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group StudyM L Slovak, K J Kopecky, P A Cassileth, et al.
Leukemia|July 29, 2000
High-dose cytosine arabinoside and daunorubicin induction therapy for adult patients with de novo non M3 acute myelogenous leukemia: impact of cytogenetics on achieving a complete remissionA S Stein, M R O'Donnell, M L Slovak, et al.
Blood|February 26, 2000
Predictors of therapy-related leukemia and myelodysplasia following autologous transplantation for lymphoma: an assessment of risk factorsA Krishnan, S Bhatia, M L Slovak, et al.
Leukemia|April 22, 2006
A retrospective study of 69 patients with t(6;9)(p23;q34) AML emphasizes the need for a prospective, multicenter initiative for rare 'poor prognosis' myeloid malignanciesM L Slovak, H Gundacker, C D Bloomfield, et al.
Pageof 10

Showing results (81-90 of 94) with videos related to

Sort By:
Pageof 10
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 1, 2009
Acute leukemia and myelodysplasia after adjuvant chemotherapy for breast cancer: durable remissions after hematopoietic stem cell transplantationV Pullarkat, M L Slovak, A Dagis, et al.
Blood|July 27, 1999
Frequency and clinical significance of the expression of the multidrug resistance proteins MDR1/P-glycoprotein, MRP1, and LRP in acute myeloid leukemia: a Southwest Oncology Group StudyC P Leith, K J Kopecky, I M Chen, et al.
Blood|June 5, 2001
The Burkitt-like lymphomas: a Southwest Oncology Group study delineating phenotypic, genotypic, and clinical featuresR M Braziel, D A Arber, M L Slovak, et al.
Blood|November 24, 2001
Benefit of cyclosporine modulation of drug resistance in patients with poor-risk acute myeloid leukemia: a Southwest Oncology Group studyA F List, K J Kopecky, C L Willman, et al.
Bone Marrow Transplantation|August 29, 2007
Reduced-intensity conditioning for allogeneic hematopoietic stem cell transplantation with fludarabine and melphalan is associated with durable disease control in myelodysplastic syndromeR Nakamura, R Rodriguez, J Palmer, et al.
Cancer Research|April 1, 1993
Overexpression of a M(r) 110,000 vesicular protein in non-P-glycoprotein-mediated multidrug resistanceR J Scheper, H J Broxterman, G L Scheffer, et al.
Blood|December 9, 2000
Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group StudyM L Slovak, K J Kopecky, P A Cassileth, et al.
Leukemia|July 29, 2000
High-dose cytosine arabinoside and daunorubicin induction therapy for adult patients with de novo non M3 acute myelogenous leukemia: impact of cytogenetics on achieving a complete remissionA S Stein, M R O'Donnell, M L Slovak, et al.
Blood|February 26, 2000
Predictors of therapy-related leukemia and myelodysplasia following autologous transplantation for lymphoma: an assessment of risk factorsA Krishnan, S Bhatia, M L Slovak, et al.
Leukemia|April 22, 2006
A retrospective study of 69 patients with t(6;9)(p23;q34) AML emphasizes the need for a prospective, multicenter initiative for rare 'poor prognosis' myeloid malignanciesM L Slovak, H Gundacker, C D Bloomfield, et al.
Pageof 10